BenevolentAI Investor Day Presentation Deck
Advanced laboratory capabilities help move programmes
faster, and generate data at scale for continuous innovation
Advanced capabilities
and technologies
• Fully equipped laboratory facilities; Biology,
Chemistry, CMC, DMPK.
• Highly experienced scientists across all
drug discovery disciplines
• In-house investment in CRISPR, RNA seq
and human IPSC capabilities
• Robust and secure data storage capacity
. Access to the Babraham Institute Research
facility, with state of the art High Content
Imaging and FACS capabilities.
• CROS and academic collaborations
complement and extend internal capabilities
Cambridge,
The Babraham Institute
Campus
Experimental capabilities enhance
entire drug discovery process
• Mechanism selection, Target identification,
target triage and experimental validation
• Refined, model-enabled Design-Make-Test
cycle
Closing the data loop
• Experimental data from hypothesis
validation workflows, portfolio projects and
disease relevant expression data are
integrated back to further enrich the
knowledge graph and our
representation of human biology
Work progresses rapidly from in-silico to in-vitro experimental test
Dynamic experimental feedback loop between scientists & technologists
Benevolent 40View entire presentation